Ru Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ru Li has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Zhanguo Li
Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China
5 shared publications Liyun Zhang
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi, China
3 shared publicationsXing Sun
Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China
3 shared publications- Chun Li
Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China
2 shared publications - Jian Sun
Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China
2 shared publications - Jing He
Department of Rheumatology and Immunology, Peking University People’s Hospital , Beijing
2 shared publications
Latest Publications
- 30 September 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (10) , 274
Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study
- 30 September 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (10) , 274
Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study
- Open Access
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001873
Serum S100A8 as a potential biomarker for diagnosis of antiphospholipid syndrome and risk stratification among aPL carriers
Background: Current diagnosis of antiphospholipid syndrome (APS) relies on antiphospholipid antibodies (aPL) testing, but false-positive aPL results and asymptomatic aPL carriers pose significant clinical challenges. The importance of S100A8 in thrombosis has been demonstrated, yet its potential role in APS has received little attention. This study aimed to assess serum S100A8 for APS diagnosis and risk stratification among aPL carriers. Methods: Serum S100A8 levels were measured by ELISA in healthy controls (HCs), aPL carriers without manifestation and patients with APS. Receiver operating characteristic curves were used to evaluate the diagnostic performance of APS. Logistic regression was performed to identify independent variables associated with obstetric morbidity among female aPL carriers. Results: The study enrolled 120 HCs, 57 aPL carriers and 114 patients with APS. Serum S100A8 levels were significantly higher in aPL carriers (median 44.3 (IQR 35.6–75.4) ng/mL, p<0.001) and patients with APS (52.8 (37.2–79.2) ng/mL, p<0.001) compared with HCs (25 (21.6–31.1) ng/mL). S100A8 showed good diagnostic accuracy for APS (area under the curve (AUC)=0.854, 95% CI 0.803 to 0.907, p<0.001), with similar performance for thrombotic APS (AUC=0.819, 95% CI 0.747 to 0.891, p<0.001) and obstetric APS (AUC=0.874, 95% CI 0.821 to 0.926, p<0.001). Multivariate logistic regression revealed that S100A8 positivity was independently associated with increased obstetric APS risk among aPL carriers (OR 3.335, 95% CI 1.010 to 11.012, p=0.048). Conclusion: S100A8 may serve as a complementary biomarker for the diagnosis and risk stratification of APS, especially in female aPL carriers at risk of obstetric morbidity. These findings support further investigation into its clinical and mechanistic role in APS pathogenesis.
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001873
Open AccessSerum S100A8 as a potential biomarker for diagnosis of antiphospholipid syndrome and risk stratification among aPL carriers
Background: Current diagnosis of antiphospholipid syndrome (APS) relies on antiphospholipid antibodies (aPL) testing, but false-positive aPL results and asymptomatic aPL carriers pose significant clinical challenges. The importance of S100A8 in thrombosis has been demonstrated, yet its potential role in APS has received little attention. This study aimed to assess serum S100A8 for APS diagnosis and risk stratification among aPL carriers. Methods: Serum S100A8 levels were measured by ELISA in healthy controls (HCs), aPL carriers without manifestation and patients with APS. Receiver operating characteristic curves were used to evaluate the diagnostic performance of APS. Logistic regression was performed to identify independent variables associated with obstetric morbidity among female aPL carriers. Results: The study enrolled 120 HCs, 57 aPL carriers and 114 patients with APS. Serum S100A8 levels were significantly higher in aPL carriers (median 44.3 (IQR 35.6–75.4) ng/mL, p<0.001) and patients with APS (52.8 (37.2–79.2) ng/mL, p<0.001) compared with HCs (25 (21.6–31.1) ng/mL). S100A8 showed good diagnostic accuracy for APS (area under the curve (AUC)=0.854, 95% CI 0.803 to 0.907, p<0.001), with similar performance for thrombotic APS (AUC=0.819, 95% CI 0.747 to 0.891, p<0.001) and obstetric APS (AUC=0.874, 95% CI 0.821 to 0.926, p<0.001). Multivariate logistic regression revealed that S100A8 positivity was independently associated with increased obstetric APS risk among aPL carriers (OR 3.335, 95% CI 1.010 to 11.012, p=0.048). Conclusion: S100A8 may serve as a complementary biomarker for the diagnosis and risk stratification of APS, especially in female aPL carriers at risk of obstetric morbidity. These findings support further investigation into its clinical and mechanistic role in APS pathogenesis.
- 27 September 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Biopsychosocial determinants and gender disparities in health-related quality of life among rheumatoid arthritis patients: a nationwide multicentre study in China
Full Papers; Authors: Y. Zhu, H. Xu, L. Zhang, Y. Huo, R. Wu, L. Wu, L. Lei, L. Geng, C. Tan, X. Li, R. Li, Y. Su Women’s Rheumatoid Arthritis Research Collaborative Group
- 27 September 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Biopsychosocial determinants and gender disparities in health-related quality of life among rheumatoid arthritis patients: a nationwide multicentre study in China
Full Papers; Authors: Y. Zhu, H. Xu, L. Zhang, Y. Huo, R. Wu, L. Wu, L. Lei, L. Geng, C. Tan, X. Li, R. Li, Y. Su Women’s Rheumatoid Arthritis Research Collaborative Group
- 8 November 2024
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (1) , 102018
Theory & practice of Treat-to-Target (T2T) in rheumatoid arthritis
- 8 November 2024
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (1) , 102018
Theory & practice of Treat-to-Target (T2T) in rheumatoid arthritis
- Open Access
- 7 June 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2346546
Platelet-to-lymphocyte ratios as a haematological marker of synovitis in rheumatoid arthritis with normal acute phase reactant level
Although normal acute phase reactants (APRs) play an important role in assessing disease activity of rheumatoid arthritis (RA), some studies pointed out the discordance between disease activity and APR level. Neutrophil-to-lymphocyte ratios (NLRs), platelet-to-lymphocyte ratios (PLRs) and lymphocyte-to-monocyte ratios (LMRs) have been reported to be sensitive measures of inflammatory reaction. This study aims to explore the value of these haematological makers in assessment of APR-negative RA patients. Out of a cohort of 418 consecutive patients with RA, we enrolled 135 patients with normal APR for this study. We performed ultrasound assessments to evaluate synovitis and bone erosion in the affected joints. Synovitis was evaluated by ultrasound grey scale (GS) and power Doppler (PD) with semi-quantitative scoring (0-3). Demographic, clinical and laboratory data were collected from the patients. Disease Activity Score-28 joints (DAS28), NLR, MLR and PLR were calculated. In RA patients with normal APR, PLR exhibited a positive correlation with ultrasound-detected synovitis and bone erosion, whereas NLR, MLR showed no significant correlation with ultrasonography parameters. The area under the ROC curve (AUC) for identifying synovitis with a GS grade ≥2 based on a PLR cutoff value of ≥159.6 was 0.7868 (sensitivity: 80.95%, specificity: 74.24%). For synovitis with a PD grade ≥2, the AUC was 0.7690, using a PLR cutoff value of ≥166.1 (sensitivity: 68.0%, specificity: 83.87%). Our findings suggested that PLR might be a reliable and cost-effective marker for identifying moderate-to-severe synovitis in RA patients with normal APR.
- 7 June 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2346546
Open AccessPlatelet-to-lymphocyte ratios as a haematological marker of synovitis in rheumatoid arthritis with normal acute phase reactant level
Although normal acute phase reactants (APRs) play an important role in assessing disease activity of rheumatoid arthritis (RA), some studies pointed out the discordance between disease activity and APR level. Neutrophil-to-lymphocyte ratios (NLRs), platelet-to-lymphocyte ratios (PLRs) and lymphocyte-to-monocyte ratios (LMRs) have been reported to be sensitive measures of inflammatory reaction. This study aims to explore the value of these haematological makers in assessment of APR-negative RA patients. Out of a cohort of 418 consecutive patients with RA, we enrolled 135 patients with normal APR for this study. We performed ultrasound assessments to evaluate synovitis and bone erosion in the affected joints. Synovitis was evaluated by ultrasound grey scale (GS) and power Doppler (PD) with semi-quantitative scoring (0-3). Demographic, clinical and laboratory data were collected from the patients. Disease Activity Score-28 joints (DAS28), NLR, MLR and PLR were calculated. In RA patients with normal APR, PLR exhibited a positive correlation with ultrasound-detected synovitis and bone erosion, whereas NLR, MLR showed no significant correlation with ultrasonography parameters. The area under the ROC curve (AUC) for identifying synovitis with a GS grade ≥2 based on a PLR cutoff value of ≥159.6 was 0.7868 (sensitivity: 80.95%, specificity: 74.24%). For synovitis with a PD grade ≥2, the AUC was 0.7690, using a PLR cutoff value of ≥166.1 (sensitivity: 68.0%, specificity: 83.87%). Our findings suggested that PLR might be a reliable and cost-effective marker for identifying moderate-to-severe synovitis in RA patients with normal APR.
- 17 April 2024
- Vol. 56 (2) , 273-278
系统性红斑狼疮低疾病活动度及缓解状况的真实世界研究
研究系统性红斑狼疮(systemic lupus erythematosus,SLE)患者的真实世界低疾病活动度和临床缓解率,并分析其相关因素。 采用现场调查的研究方法,对国内11家医院1 000例SLE患者进行问卷调查,记录患者的一般资料、临床表现、实验室检查结果和治疗情况等。采用狼疮低疾病活动状态(lupus low disease activity state,LLDAS)和SLE缓解定义(definitions of remission in SLE,DORIS)评价患者低疾病活动度和临床缓解率,进一步分析符合LLDAS或DORIS缓解患者的临床特征。多因素Logistic回归分析影响LLDAS或DORIS缓解的相关因素。 1 000例SLE患者中,207例(20.7%)符合LLDAS标准,104例(10.4%)符合DORIS缓解。与不符合LLDAS或DORIS的患者相比,符合LLDAS或DORIS者高收入比例更高,病程更长,贫血、肌酐升高、红细胞沉降率增快和低白蛋白血症的发生率更低。应用羟氯喹>12个月或免疫抑制剂≥6个月的SLE患者缓解比例较高。多因素Logistic回归分析发现,红细胞沉降率增快、抗双链DNA抗体阳性、低补体血症(C3和C4)、蛋白尿及家庭收入低是不利于达到LLDAS或DORIS缓解的独立相关因素,而应用羟氯喹>12个月为达到LLDAS或DORIS缓解的保护因素。 SLE患者达到LLDAS或DORIS缓解状态的比例较低,规范应用羟氯喹和免疫抑制剂有助于患者的病情缓解。
- 17 April 2024
- Vol. 56 (2) , 273-278
系统性红斑狼疮低疾病活动度及缓解状况的真实世界研究
研究系统性红斑狼疮(systemic lupus erythematosus,SLE)患者的真实世界低疾病活动度和临床缓解率,并分析其相关因素。 采用现场调查的研究方法,对国内11家医院1 000例SLE患者进行问卷调查,记录患者的一般资料、临床表现、实验室检查结果和治疗情况等。采用狼疮低疾病活动状态(lupus low disease activity state,LLDAS)和SLE缓解定义(definitions of remission in SLE,DORIS)评价患者低疾病活动度和临床缓解率,进一步分析符合LLDAS或DORIS缓解患者的临床特征。多因素Logistic回归分析影响LLDAS或DORIS缓解的相关因素。 1 000例SLE患者中,207例(20.7%)符合LLDAS标准,104例(10.4%)符合DORIS缓解。与不符合LLDAS或DORIS的患者相比,符合LLDAS或DORIS者高收入比例更高,病程更长,贫血、肌酐升高、红细胞沉降率增快和低白蛋白血症的发生率更低。应用羟氯喹>12个月或免疫抑制剂≥6个月的SLE患者缓解比例较高。多因素Logistic回归分析发现,红细胞沉降率增快、抗双链DNA抗体阳性、低补体血症(C3和C4)、蛋白尿及家庭收入低是不利于达到LLDAS或DORIS缓解的独立相关因素,而应用羟氯喹>12个月为达到LLDAS或DORIS缓解的保护因素。 SLE患者达到LLDAS或DORIS缓解状态的比例较低,规范应用羟氯喹和免疫抑制剂有助于患者的病情缓解。
- Open Access
- 8 November 2022
- Published by BMJ in Lupus Science & Medicine
- Vol. 9 (1) , e000779
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study
Objective: Infection is a major cause of death in patients with SLE. This study aimed to explore the infection rate in patients with SLE receiving a low dose of intravenous cyclophosphamide (IV-CYC).Methods: Clinical parameters of 1022 patients with SLE from 24 hospitals in China were collected. Patients were divided into the short-interval and lower-dose (SILD, 400 mg every 2 weeks) IV-CYC group and the high-dose (HD, 500 mg/m2of body surface area every month) IV-CYC group. The clinical data and infection rate between the two groups were compared.Results: Compared with HD IV-CYC, the infection rate of the SILD IV-CYC group was significantly lower (13.04% vs 22.27%, p=0.001). Respiratory tract infection (10.28% vs 15.23%, p=0.046) and skin/soft tissue infection (1.78% vs 4.3%, p=0.040) were significantly decreased in the SILD IV-CYC group. Moreover, infections occurred most likely in patients with SLE with leucopenia (OR 2.266, 95% CI 1.322 to 3.887, p=0.003), pulmonary arterial hypertension (OR 2.756, 95% CI 1.249 to 6.080, p=0.012) and >15 mg/day of glucocorticoid (OR 2.220, 95% CI 1.097 to 4.489, p=0.027).Conclusions: SILD IV-CYC showed a lower frequency of infection events than high-dose IV-CYC in patients with SLE.
- 8 November 2022
- Published by BMJ in Lupus Science & Medicine
- Vol. 9 (1) , e000779
Open AccessComparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study
Objective: Infection is a major cause of death in patients with SLE. This study aimed to explore the infection rate in patients with SLE receiving a low dose of intravenous cyclophosphamide (IV-CYC).Methods: Clinical parameters of 1022 patients with SLE from 24 hospitals in China were collected. Patients were divided into the short-interval and lower-dose (SILD, 400 mg every 2 weeks) IV-CYC group and the high-dose (HD, 500 mg/m2of body surface area every month) IV-CYC group. The clinical data and infection rate between the two groups were compared.Results: Compared with HD IV-CYC, the infection rate of the SILD IV-CYC group was significantly lower (13.04% vs 22.27%, p=0.001). Respiratory tract infection (10.28% vs 15.23%, p=0.046) and skin/soft tissue infection (1.78% vs 4.3%, p=0.040) were significantly decreased in the SILD IV-CYC group. Moreover, infections occurred most likely in patients with SLE with leucopenia (OR 2.266, 95% CI 1.322 to 3.887, p=0.003), pulmonary arterial hypertension (OR 2.756, 95% CI 1.249 to 6.080, p=0.012) and >15 mg/day of glucocorticoid (OR 2.220, 95% CI 1.097 to 4.489, p=0.027).Conclusions: SILD IV-CYC showed a lower frequency of infection events than high-dose IV-CYC in patients with SLE.
- Open Access
- 27 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5709
A Rare Case of Neurosarcoidosis Overlapped with Sjogren’s Syndrome
The coexisting of sarcoidosis and Sjögren’s syndrome (SS) has long been neglected since sarcoidosis is considered as an exclusion criterion for SS. We described a 55-year-old woman, who was diagnosed with coexisting neurosarcoidosis and Sjögren’s syndrome for 16 years. She presented with erythema nodosum, progressive sensory and motor impairment of the extremities, dry mouth, and dry eyes. High-resolution computed tomography (HRCT) of the chest showed symmetrical pulmonary micronodules, interstitial changes, and enlarged mediastinal lymph nodes. Spine magnetic resonance imaging (MRI) showed syringomyelia and thickening of the T3-9 spinal cord. She was with positive ANA and anti-SSA antibodies, impaired function of the lacrimal, salivary gland and renal tubules. Biopsy of skin and lung nodules revealed non-caseous granuloma. Salivary gland biopsy showed focal lymphocyte infiltration. Classification criteria for sarcoidosis and Sjogren’s syndrome were fulfilled in this patient based on clinical and laboratory features. This case extends our understanding of overlapped Sjogren’s syndrome with sarcoidosis and provides a referential value for clinical diagnosis.
- 27 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5709
Open AccessA Rare Case of Neurosarcoidosis Overlapped with Sjogren’s Syndrome
The coexisting of sarcoidosis and Sjögren’s syndrome (SS) has long been neglected since sarcoidosis is considered as an exclusion criterion for SS. We described a 55-year-old woman, who was diagnosed with coexisting neurosarcoidosis and Sjögren’s syndrome for 16 years. She presented with erythema nodosum, progressive sensory and motor impairment of the extremities, dry mouth, and dry eyes. High-resolution computed tomography (HRCT) of the chest showed symmetrical pulmonary micronodules, interstitial changes, and enlarged mediastinal lymph nodes. Spine magnetic resonance imaging (MRI) showed syringomyelia and thickening of the T3-9 spinal cord. She was with positive ANA and anti-SSA antibodies, impaired function of the lacrimal, salivary gland and renal tubules. Biopsy of skin and lung nodules revealed non-caseous granuloma. Salivary gland biopsy showed focal lymphocyte infiltration. Classification criteria for sarcoidosis and Sjogren’s syndrome were fulfilled in this patient based on clinical and laboratory features. This case extends our understanding of overlapped Sjogren’s syndrome with sarcoidosis and provides a referential value for clinical diagnosis.
- Open Access
- 8 March 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (8) , 962-970
Features of hyperintense white matter lesions and clinical relevance in systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by complex and various clinical manifestations. The study aimed to analyze clinical features and cerebral magnetic resonance imaging (MRI) changes of hyperintense white matter (WM) lesions in SLE patients. Methods: This was a retrospective study based on a consecutive cohort of 1191 SLE patients; 273 patients for whom cerebral MRI data were available were enrolled to assess hyperintense WM lesions associated with SLE. Patients were assigned to two groups, i.e., with or without hyperintense WM lesions. The MRI assessment showed that the hyperintense WM lesions could be classified into three categories: type A, periventricular hyperintense WM lesions; type B, subcortical hyperintense WM lesions; and type C, multiple discrete hyperintense WM lesions. The clinical and MRI characteristics were analyzed. Factors related to hyperintense WM lesions were identified by multivariate logistic regression analysis. Results: Among the 273 SLE patients with available cerebral MRI scans, 35.9% (98/273) had hyperintense WM lesions associated with SLE. The proportions of types A, B, and C were 54.1% (53/98), 11.2% (11/98), and 92.9% (91/98), respectively. Fifty-one percents of the patients showed an overlap of two or three types. Type C was the most common subgroup to be combined with other types. Compared with those without hyperintense WM lesions, the patients with hyperintense WM lesions were associated with neuropsychiatric SLE (NPSLE), lupus nephritis (LN), hypertension, and hyperuricemia (P = 0.002, P = 0.018, P = 0.045, and P = 0.036, respectively). Significantly higher rates of polyserous effusions and cardiac involvement were found in the patients with hyperintense WM lesions (P = 0.029 and P = 0.027, respectively), and these patients were more likely to present with disease damage (P < 0.001). In addition, the patients with hyperintense WM lesions exhibited a higher frequency of proteinuria (P = 0.009) and higher levels of CD8 + T cells (P = 0.005). In the multivariate logistic analysis, hyperuricemia and higher CD8+ T cells percentages were significantly correlated with hyperintense WM lesions in SLE patients (P = 0.019; OR 2.129, 95% confidence interval [CI] 1.313–4.006 and P < 0.001; OR 1.056, 95% CI 1.023–1.098, respectively). Conclusions: Hyperintense WM lesions are common in SLE patients and significantly associated with systemic involvement, including NPSLE, LN, polyserous effusions, cardiac involvement, and disease damage. Hyperuricemia and a higher number of CD8+ T cells were independent factors associated with hyperintense WM lesions in SLE.
- 8 March 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (8) , 962-970
Open AccessFeatures of hyperintense white matter lesions and clinical relevance in systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by complex and various clinical manifestations. The study aimed to analyze clinical features and cerebral magnetic resonance imaging (MRI) changes of hyperintense white matter (WM) lesions in SLE patients. Methods: This was a retrospective study based on a consecutive cohort of 1191 SLE patients; 273 patients for whom cerebral MRI data were available were enrolled to assess hyperintense WM lesions associated with SLE. Patients were assigned to two groups, i.e., with or without hyperintense WM lesions. The MRI assessment showed that the hyperintense WM lesions could be classified into three categories: type A, periventricular hyperintense WM lesions; type B, subcortical hyperintense WM lesions; and type C, multiple discrete hyperintense WM lesions. The clinical and MRI characteristics were analyzed. Factors related to hyperintense WM lesions were identified by multivariate logistic regression analysis. Results: Among the 273 SLE patients with available cerebral MRI scans, 35.9% (98/273) had hyperintense WM lesions associated with SLE. The proportions of types A, B, and C were 54.1% (53/98), 11.2% (11/98), and 92.9% (91/98), respectively. Fifty-one percents of the patients showed an overlap of two or three types. Type C was the most common subgroup to be combined with other types. Compared with those without hyperintense WM lesions, the patients with hyperintense WM lesions were associated with neuropsychiatric SLE (NPSLE), lupus nephritis (LN), hypertension, and hyperuricemia (P = 0.002, P = 0.018, P = 0.045, and P = 0.036, respectively). Significantly higher rates of polyserous effusions and cardiac involvement were found in the patients with hyperintense WM lesions (P = 0.029 and P = 0.027, respectively), and these patients were more likely to present with disease damage (P < 0.001). In addition, the patients with hyperintense WM lesions exhibited a higher frequency of proteinuria (P = 0.009) and higher levels of CD8 + T cells (P = 0.005). In the multivariate logistic analysis, hyperuricemia and higher CD8+ T cells percentages were significantly correlated with hyperintense WM lesions in SLE patients (P = 0.019; OR 2.129, 95% confidence interval [CI] 1.313–4.006 and P < 0.001; OR 1.056, 95% CI 1.023–1.098, respectively). Conclusions: Hyperintense WM lesions are common in SLE patients and significantly associated with systemic involvement, including NPSLE, LN, polyserous effusions, cardiac involvement, and disease damage. Hyperuricemia and a higher number of CD8+ T cells were independent factors associated with hyperintense WM lesions in SLE.
- Open Access
- 12 August 2021
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 15, 100240
Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region
- 12 August 2021
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 15, 100240
Open AccessClinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region